NDA 16680, held by Parke Davis. Liotrix (T4;T3).
As of Nov 13, 2026, NDA 16680 (Euthroid-0.5, Euthroid-1, Euthroid-2), held by Parke Davis, was not approved, with 0 approved supplements and 0 published complete response letters.
| Euthroid-0.50.03MG;0.0075MG · tablet;oral | Liotrix (T4;T3) | Discontinued |
| Euthroid-10.06MG;0.015MG · tablet;oral | Liotrix (T4;T3) | Discontinued |
| Euthroid-20.12MG;0.03MG · tablet;oral | Liotrix (T4;T3) | Discontinued |
| Euthroid-30.18MG;0.045MG · tablet;oral | Liotrix (T4;T3) | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
